Amgen Inc. $AMGN Stock: BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Lowers Holdings

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 13.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,140 shares of the medical research company’s stock after selling 10,715 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Amgen were worth $29,565,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Quest 10 Wealth Builders Inc. boosted its holdings in Amgen by 220.0% in the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 55 shares during the last quarter. Wellington Altus USA Inc. grew its stake in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares in the last quarter. Nvwm LLC increased its holdings in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC increased its holdings in Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after purchasing an additional 42 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co purchased a new stake in Amgen during the 3rd quarter worth approximately $38,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.8%

NASDAQ:AMGN opened at $435.52 on Friday. The company has a market cap of $235.58 billion, a PE ratio of 25.26, a P/E/G ratio of 3.03 and a beta of 0.43. The business’s 50 day moving average is $430.44 and its two-hundred day moving average is $383.81. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $5.64 EPS. On average, analysts predict that Amgen Inc. will post 23.44 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s payout ratio is presently 58.47%.

Analysts Set New Price Targets

Several equities analysts have recently commented on AMGN shares. Bank of America increased their target price on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Citigroup upped their price target on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Royal Bank Of Canada upped their price target on shares of Amgen from $430.00 to $470.00 and gave the company an “outperform” rating in a report on Wednesday, November 4th. Cantor Fitzgerald increased their price objective on shares of Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $428.62.

Get Our Latest Analysis on Amgen

Amgen Company Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.